Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug could shrink rare joint tumors without surgery

NCT ID NCT05417789

Disease control Sponsor: SynOx Therapeutics Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times

Summary

This study tests an investigational drug called emactuzumab for people with a rare joint tumor (TGCT) that can't be removed surgically. About 128 participants will receive either the drug or a placebo to see if it shrinks tumors and improves joint function. The goal is to offer a non-surgical treatment option for this condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 128 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Sep 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \>12 years * Biopsy-confirmed (standard of care diagnosis history) local or diffuse TGCT where surgical resection would be associated with predicted worsening functional limitations through surgical joint damage, and/or subject has an anticipated high risk of early recurrence as determined by a multidisciplinary tumour board or equivalent, or any other morbidity associated with the surgery, and/or surgical treatment is not expected to improve the clinical outcomes of the subject. * Measurable disease: longest diameter ≥20 mm. * Adequate organ and bone marrow function * If a woman of childbearing potential (WOCBP), must have a negative pregnancy test prior to starting treatment and agree to use a highly effective method of contraception * Participants must have given written consent Exclusion Criteria: * If a female, the subject is pregnant or breast feeding. * Medical conditions, including auto-immune, requiring systemic immunosuppression. Any systemic treatment for these conditions (eg, glucocorticoids) is not allowed within 4 weeks of Screening and during the study. * Known metastatic TGCT or other active cancer that requires concurrent or planned treatment * Received systemic therapy for TGCT (investigational or approved) targeting CSF-1 or CSF-1R or any multi-tyrosine kinase inhibitor (eg nilotinib and imatinib) within 3 months prior to screening * Any surgery, chemotherapy or radiotherapy within 3 months of screening * Unresolved clinically significant toxicity from a previous treatment or any history of serious liver toxicity. * Current or chronic history of liver disease. * Inadequate renal and liver function * Systemic antiretroviral therapy within 3 months of baseline * Within 6 months of baseline has experienced: clinically significant myocardial infarction, severe/unstable angina pectoris, congestive heart failure New York Heart Association (NYHA) Class III or IV, or pulmonary disease (NYHA Criteria 1994) including severe thromboembolic event; incompletely healed clinically significant wounds, including bone fractures; pathological fracture or significant hypercalcaemia.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Tenosynovial giant cell tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

synovitis tenosynovial giant cell tumor tenosynovial giant cell tumor, diffuse type

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TGCT

Contacts and locations

Locations

  • AP-HP - Hôpital Cochin - Port-Royal, site Cochin

    Paris, Paris, 75014, France

  • Arthur J.E. Child Comprehensive Cancer Centre

    Calgary, Alberta, T2N 4N1, Canada

  • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone

    Palermo, Sicily, 90127, Italy

  • Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes

    Lyon, Rhône, 69373, France

  • Cliniques Universitaires Saint-Luc

    Woluwe-Saint-Lambert, Brussels Capital, 1200, Belgium

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, 20133, Italy

  • Fondazione Policlinico Universitario Campus Bio-Medico

    Rome, Lazio, 00128, Italy

  • Fondazione del Piemonte per l'Oncologia (IRCCS)

    Candiolo, Piedmont, 10060, Italy

  • Hospital Universitari i Politecnic La Fe de Valencia

    Valencia, 46026, Spain

  • Hospital Universitario Fundacion Jimenez Diaz

    Zaragoza, Zaragoza, 50009, Spain

  • Hospital Universitario Virgen del Rocio - PPDS

    Seville, 41013, Spain

  • Hospital de La Santa Creu i Sant Pau

    Barcelona, 8041, Spain

  • IRCCS lstituto Ortopedico Rizzoli

    Bologna, 40136, Italy

  • Institut Bergonie - PPDS

    Bordeaux, Gironde, 33000, France

  • Institut Curie - Hôpital de Paris

    Paris, 75248, France

  • Institut de Cancerologie de Ouest - Saint Herblain

    Saint-Herblain, Loire-Atlantique, 44115, France

  • Istituti Fisioterapici Ospitalieri - IRCCS Istituto Nazionale Tumori Regina Elena

    Rome, Lazio, 00144, Italy

  • Leids Universitair Medisch Centrum

    Leiden, 2333 ZA, Netherlands

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • McGill University Health Centre (MUHC)

    Montreal, Quebec, H1T 2M4, Canada

  • MedStar Washington Hospital Center

    Georgetown, Washington, 20010, United States

  • NextGen Oncology

    Beverly Hills, California, 90212, United States

  • Oncopole Claudius Regaud Oncologie Médicale

    Toulouse, 31059, France

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2M9, Canada

  • Seoul National University Hospital

    Seoul, 3080, South Korea

  • Skanes Universitetssjukhus Lund

    Lund, Skåne County, 222 42, Sweden

  • St James's University Hospital

    Leeds, LS9 7TF, United Kingdom

  • Taipei Veterans General Hospital

    Taipei, 112, Taiwan

  • The Ohio State University

    Columbus, Ohio, 43201, United States

  • UNICANCER - Centre Oscar Lambret

    Lille, 59000, France

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California, 90089, United States

  • University College Hospital

    London, NW1 2BU, United Kingdom

  • Universitäts Kinderspital Beider Basel (UKBB)

    Basel, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.